. 2015 Aug 5;29(9):1269–1285. doi: 10.1210/me.2014-1406

Table 2.

PTH-Induced Bone Gain Data

	WT		Nmp4^−/−		Two-Way ANOVA P Values
	VEH	PTH	VEH	PTH	Genotype	Treatment	Gene × Treat
Distal femur
4 wk
Conn.D (mm⁻³)	3.180 ± 3.870	33.230 ± 26.730	9.681 ± 15.979	67.533 ± 14.111	.0018	<.0001	.03
SMI	3.752 ± 0.437	3.013 ± 0.384	3.472 ± 0.327	2.514 ± 0.113	.0025	<.0001	.36
Tb.N (mm⁻¹)	2.100 ± 0.519	2.441 ± 0.281	2.712 ± 0.241	2.833 ± 0.224	.0002	.06	.36
Tb.Th (mm)	0.039 ± 0.010	0.042 ± 0.007	0.033 ± 0.003	0.044 ± 0.003	.54	.004	.09
Tb.Sp (mm)	0.510 ± 0.157	0.409 ± 0.051	0.370 ± 0.036	0.342 ± 0.032	.0019	.04	.24
8 wk
Conn.D (mm⁻³)	3.123 ± 5.307	38.658 ± 14.910	0.982 ± 1.103	58.128 ± 13.570	.03	<.0001	.0064
SMI	3.808 ± 0.479	2.470 ± 0.284	3.589 ± 0.218	2.262 ± 0.141	.05	<.0001	.96
Tb.N (mm⁻¹)	2.132 ± 0.297	2.164 ± 0.431	2.286 ± 0.145	2.552 ± 0.277	.02	.17	.28
Tb.Th (mm)	0.037 ± 0.006	0.048 ± 0.005	0.030 ± 0.004	0.049 ± 0.003	.12	<.0001	.02
Tb.Sp (mm)	0.476 ± 0.072	0.471 ± 0.109	0.438 ± 0.033	0.378 ± 0.045	.01	.20	.27
L5 vertebra
4 wk
Tb.N (mm⁻¹)	3.453 ± 0.451	4.875 ± 0.587	3.891 ± 0.504	5.518 ± 0.381	.0049	<.0001	.56
Tb.Th (mm)	0.051 ± 0.002	0.049 ± 0.002	0.054 ± 0.004	0.051 ± 0.001	.04	.03	.60
Tb.Sp (mm)	0.246 ± 0.021	0.224 ± 0.030	0.229 ± 0.021	0.197 ± 0.021	.02	.0036	.52
8 weeks
Tb.N (mm⁻¹)	4.046 ± 0.917	5.648 ± 1.191	3.627 ± 0.235	5.906 ± 0.754	.79	<.0001	.26
Tb.Th (mm)	0.053 ± 0.003	0.049 ± 0.004	0.055 ± 0.001	0.054 ± 0.001	.0018	.0044	.09
Tb.Sp (mm)	0.239 ± 0.021	0.206 ± 0.037	0.256 ± 0.020	0.186 ± 0.023	.86	<.0001	.05

μCT (distal femur and L5 vertebra) from ovx WT and ovx Nmp4^−/− mice after 4 and 8 weeks of PTH/VEH therapy. Data are average ± SD, number of mice/experimental group = 8–9. Statistical significance was set at P ≤ .05, and differences were determined using a two-way ANOVA.